Imgn investors hub
Witryna11 kwi 2024 · About IMGN. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant … WitrynaIMGN.PRO jest polskim wydawcą, dystrybutorem i producentem gier wideo przeznaczonych na komputery osobiste i konsole. Oprócz autorskich produkcji w jej portfolio wydawniczym można znaleźć ...
Imgn investors hub
Did you know?
Witryna16 gru 2015 · Interesting IMGN Put And Call Options For July 2024 Monday, November 21, 11:03 AM. Notable Tuesday Option Activity: BC, IMGN, DDOG Tuesday, … Witryna12 mar 2007 · Presentation of MARINE and ANCHOR analyses at AHA showing significant reduction of remnant-like particle cholesterol (17 Nov 2014) Marine & …
Witryna5 kwi 2024 · IMGN’s stock style is Small Core. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining … Witryna6 kwi 2024 · Title. Mar 29. ImmunoGen (NASDAQ:IMGN) investors are sitting on a loss of 66% if they invested five years ago. Mar 25. ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting. Mar 3. ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2024 Earnings Call Transcript. Mar 2. …
Witryna1 mar 2024 · The Investor Relations website contains information about ImmunoGen, Inc.'s business for stockholders, potential investors, and financial analysts. WitrynaInvestorsHub - NYSE, NASDAQ, AMEX, OTCBB, Pink Sheet Stock Message Boards, Stock Charts, Stock Quotes, Level II and Market News. S&P 500.
Witryna30 wrz 2024 · Weighted average shares outstanding increased to 253.5 million for the 2024 period from 204.8 million in the prior year. ImmunoGen had $309.5 million in cash and cash equivalents as of September 30, 2024, compared with $478.8 million as of December 31, 2024. Cash used in operations was $169.6 million for the first nine …
WitrynaBusiness Wire. ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian … raymond shores rv resort for saleWitrynaInstitutional Ownership and Shareholders. ImmunoGen, Inc. (US:IMGN) has 394 institutional owners and shareholders that have filed 13D/G or 13F forms with the … simplify 5 2/3Witryna6 kwi 2024 · IMGN Stock Message Board for Investors. ImmunoGen Inc. Stock Price, News and Company Updates. Message Board Total Posts: 67 raymond shores rv lots for saleWitryna15 gru 2024 · Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks ... simplify 52/60Witryna10 kwi 2024 · ImmunoGen (IMGN) Investor Presentation - Slideshow Nov 20. Analysts increase revenue estimates to US$79.5m Nov 13. Third quarter 2024 earnings released: US$0.13 loss per share Nov 08. Revenue beats expectations, earnings disappoint Nov 08. ImmunoGen EPS beats by $0.06, beats on revenue simplify 52/3Witryna15 lut 2024 · SGO/SORAYA Investor Event. Listen to webcast. Supporting Materials. View Presentation 1.1 MB. Mar 9, 2024 12:50 PM EST Cowen 42nd Annual Health Care Conference - Ovarian Cancer Panel. Listen to webcast. Feb 25, 2024 8:00 AM EST ImmunoGen Full Year 2024 Operating Results Conference Call. Listen to webcast ... simplify 52/4Witryna8 kwi 2024 · ImmunoGen, Inc. Message board - Online Community of active, educated investors researching and discussing ImmunoGen, Inc. Stocks. Home Recent Posts … simplify 52/65